Martha E. Anderson

3.1k total citations · 2 hit papers
38 papers, 2.1k citations indexed

About

Martha E. Anderson is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Martha E. Anderson has authored 38 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 21 papers in Radiology, Nuclear Medicine and Imaging and 13 papers in Molecular Biology. Recurrent topics in Martha E. Anderson's work include Monoclonal and Polyclonal Antibodies Research (21 papers), HER2/EGFR in Cancer Research (18 papers) and Multiple Myeloma Research and Treatments (8 papers). Martha E. Anderson is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (21 papers), HER2/EGFR in Cancer Research (18 papers) and Multiple Myeloma Research and Treatments (8 papers). Martha E. Anderson collaborates with scholars based in United States, Netherlands and South Korea. Martha E. Anderson's co-authors include Peter D. Senter, Svetlana O. Doronina, Robert P. Lyon, Tim D. Bovee, Joshua H. Hunter, Jocelyn R. Setter, Patrick Burke, Mechthild Jonas, Steven Duniho and Jamie B. Miyamoto and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Martha E. Anderson

38 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index

2015 390 citations Robert P. Lyon, Tim D. Bovee et al. Nature Biotechnology profile →
Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates

2014 358 citations Robert P. Lyon, Jocelyn R. Setter et al. Nature Biotechnology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Martha E. Anderson United States	18	1.4k	1.1k	865	288	280	38	2.1k
Brian E. Toki United States	14	1.6k 1.2×	1.4k 1.3×	1.1k 1.3×	325 1.1×	549 2.0×	15	2.9k
Roger F. Zabinski United States	11	1.4k 1.0×	1.2k 1.1×	808 0.9×	197 0.7×	206 0.7×	11	2.1k
Tim D. Bovee United States	6	1.5k 1.1×	1.4k 1.3×	881 1.0×	155 0.5×	314 1.1×	10	2.2k
Wayne C. Widdison United States	17	1.8k 1.3×	1.7k 1.5×	1.1k 1.2×	219 0.8×	493 1.8×	34	2.8k
Elaine Mai United States	13	1.7k 1.2×	1.5k 1.4×	809 0.9×	256 0.9×	127 0.5×	20	2.3k
Dana F. Chace United States	15	1.9k 1.4×	1.8k 1.6×	1.1k 1.2×	550 1.9×	228 0.8×	22	3.1k
Brian A. Mendelsohn United States	26	1.5k 1.1×	1.5k 1.3×	1.0k 1.2×	151 0.5×	667 2.4×	39	2.6k
Michael Torgov United States	11	983 0.7×	941 0.8×	639 0.7×	136 0.5×	167 0.6×	19	1.6k
Robert P. Lyon United States	22	1.4k 1.1×	1.4k 1.2×	984 1.1×	202 0.7×	340 1.2×	45	2.4k
Kathryn L. Parsons United States	6	2.1k 1.6×	1.8k 1.6×	958 1.1×	262 0.9×	145 0.5×	11	2.7k

Countries citing papers authored by Martha E. Anderson

Since Specialization

Citations

This map shows the geographic impact of Martha E. Anderson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martha E. Anderson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martha E. Anderson more than expected).

Fields of papers citing papers by Martha E. Anderson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martha E. Anderson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martha E. Anderson. The network helps show where Martha E. Anderson may publish in the future.

Co-authorship network of co-authors of Martha E. Anderson

This figure shows the co-authorship network connecting the top 25 collaborators of Martha E. Anderson. A scholar is included among the top collaborators of Martha E. Anderson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martha E. Anderson. Martha E. Anderson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Heiser, Ryan A., Anthony Cao, Weiping Zeng, et al.. (2023). Brentuximab Vedotin–Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity. Molecular Cancer Therapeutics. 23(1). 68–83. 28 indexed citations

Neumann, Christopher S., Martha E. Anderson, Julia H. Cochran, et al.. (2018). Targeted Delivery of Cytotoxic NAMPT Inhibitors Using Antibody–Drug Conjugates. Molecular Cancer Therapeutics. 17(12). 2633–2642. 32 indexed citations

Sussman, Django, Lori Westendorf, David W. Meyer, et al.. (2018). Engineered cysteine antibodies: an improved antibody-drug conjugate platform with a novel mechanism of drug-linker stability. Protein Engineering Design and Selection. 31(2). 47–54. 47 indexed citations

Burke, Patrick, Scott C. Jeffrey, Joshua H. Hunter, et al.. (2016). Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody–Drug Conjugates. Molecular Cancer Therapeutics. 16(1). 116–123. 110 indexed citations

Lyon, Robert P., Tim D. Bovee, Svetlana O. Doronina, et al.. (2015). Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nature Biotechnology. 33(7). 733–735. 390 indexed citations breakdown →

Ryan, Maureen C., Brian Schimpf, Martha E. Anderson, et al.. (2015). SGN-CD19B, a Pyrrolobenzodiazepine (PBD)-Based Anti-CD19 Drug Conjugate, Demonstrates Potent Preclinical Activity Against B-Cell Malignancies. Blood. 126(23). 594–594. 4 indexed citations

Epps, Heather A. Van, Kerry Klussman, Martha E. Anderson, et al.. (2015). Abstract 2541: Preclinical results of SGN-CD19A in combination with R-ICE or R-CHOP in non-Hodgkin lymphoma models. Cancer Research. 75(15_Supplement). 2541–2541. 3 indexed citations

Sussman, Django, Leia M. Smith, Martha E. Anderson, et al.. (2014). SGN–LIV1A: A Novel Antibody–Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer. Molecular Cancer Therapeutics. 13(12). 2991–3000. 104 indexed citations

Lyon, Robert P., Jocelyn R. Setter, Tim D. Bovee, et al.. (2014). Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates. Nature Biotechnology. 32(10). 1059–1062. 358 indexed citations breakdown →

10.

Sandall, Sharsti, Martha E. Anderson, Mechthild Jonas, et al.. (2014). Abstract 2647: SGN-CD70A, a novel and highly potent anti-CD70 ADC, induces double-strand DNA breaks and is active in models of MDR+ renal cell carcinoma (RCC) and non-Hodgkin lymphoma (NHL). Cancer Research. 74(19_Supplement). 2647–2647. 9 indexed citations

11.

Okeley, Nicole M., Stephen C. Alley, Martha E. Anderson, et al.. (2013). Development of orally active inhibitors of protein and cellular fucosylation. Proceedings of the National Academy of Sciences. 110(14). 5404–5409. 147 indexed citations

12.

Jeffrey, Scott C., Patrick Burke, David W. Meyer, et al.. (2012). Abstract 4631: Anti-CD70 antibody-drug conjugates containing pyrrolobenzodiazepine dimers demonstrate robust antitumor activity. Cancer Research. 72(8_Supplement). 4631–4631. 1 indexed citations

13.

Sutherland, May Kung, Changpu Yu, Martha E. Anderson, et al.. (2010). 5-Azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia. mAbs. 2(4). 440–448. 24 indexed citations

14.

Ryan, Maureen C., Heather Kostner, Karen A. Gordon, et al.. (2010). Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody–drug conjugate SGN-75. British Journal of Cancer. 103(5). 676–684. 68 indexed citations

15.

Leavey, Patrick J., Julia Glade Bender, Leo Mascarenhas, et al.. (2010). Feasibility of bevacizumab (NSC 704865, BB-IND# 7921) combined with vincristine, topotecan, and cyclophosphamide in patients with first recurrent Ewing sarcoma (EWS): A Children's Oncology Group (COG) study.. Journal of Clinical Oncology. 28(15_suppl). 9552–9552. 9 indexed citations

16.

Burke, Patrick, Brian E. Toki, David W. Meyer, et al.. (2009). Novel immunoconjugates comprised of streptonigrin and 17-amino-geldanamycin attached via a dipeptide-p-aminobenzyl-amine linker system. Bioorganic & Medicinal Chemistry Letters. 19(10). 2650–2653. 20 indexed citations

17.

Alley, Stephen C., Xinqun Zhang, Nicole M. Okeley, et al.. (2009). The Pharmacologic Basis for Antibody-Auristatin Conjugate Activity. Journal of Pharmacology and Experimental Therapeutics. 330(3). 932–938. 100 indexed citations

18.

McDonagh, Charlotte F., Kristine M. Kim, Eileen Turcott, et al.. (2008). Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index. Molecular Cancer Therapeutics. 7(9). 2913–2923. 60 indexed citations

19.

Smith, Leia M., Albina Nesterova, Maureen C. Ryan, et al.. (2008). CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. British Journal of Cancer. 99(1). 100–109. 218 indexed citations

20.

Burrell, Robert & Martha E. Anderson. (1973). The induction of fibrogenesis by silica-treated alveolar macrophages. Environmental Research. 6(4). 389–394. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact